NASDAQ · HSIC

Henry Schein, Inc.

Healthcare · Medical - Distribution

$85.04▼ 1.99% ($1.73)at close

As of 4:00 PM ET

52-week

$61.95$92.18

Market cap

$9.69B

P/E

What the market price implies · Reverse DCF

To support a price of $85.04, this model requires Stage 1 FCFF to grow by 3.37%/yr over the next 5 years, compounded annually.

Historical FCFF grew by 4.07%/yr over the past 10 years. The required annual growth rate is 0.70 percentage points lower.

Selected forecast · Base scenario

4.07%/yr · Stage 1 default · years 1–5

Annual overrides take precedence over the Stage 1 default.

Market-implied · Other assumptions held fixed

3.37%/yr · Stage 1 · years 1–5

Stage 1 growth is solved while Stage 2 growth, terminal growth, discount inputs, and annual overrides remain fixed. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Cash-flow DCF

Price used

$85.04

Estimated value / share

$89.05

Base scenario

This estimate is 4.71% above the price used.

USD · TTM ending 2026-06-27

FCFF base normalized by replacing latest capex with the company's trailing median capex-to-revenue ratio.

Historical FCFF CAGR and the default growth rates are taken from the raw historical series. The valuation base is normalized for the current-period DCF.

Reported total debt includes capitalised leases (~9% of the total). They are excluded from net debt and from the WACC weights because rent is already charged inside operating income. The Net Debt shown here is therefore lower than the balance-sheet figure elsewhere on this page.

Stage 1 4.07% · Stage 2 3.5% · Discount rate 7.89%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future free cash flow, discounted to its value today.

Price timestamp: Sep 17, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-27
Data refreshed: Sep 17, 2026, 10:20 PM UTC · cache

Why this method?

FCFF is positive, but the year-to-year swings are too large for a direct CAGR. Normalize the cash-flow base first, then run DCF.

Is FCFF positive and has it been for 3+ consecutive years? 26 consecutive positive FCFF years are available.

Is FCFF stable (not swinging >30% year to year)? The largest recent FCFF swing is 114.1%.

Price vs Fundamentals

Why The Stock Is Moving

Fundamentals are supporting the moveModerate confidence

1Y Price: 26.23%Revenue (TTM): 6.49%FCF (TTM): 50.56%P/FCF: 59th pct

What changed

The stock rose 26.23% over the last year. Revenue grew 6.49% over the trailing twelve months. Operating margin moved from 6.06% to 5.69%. Free cash flow grew 50.56% over the trailing twelve months.

What the market seems to be pricing

The stock move broadly lines up with stronger business momentum, and the shares are still only around the 59th percentile of their historical P/FCF range.

What would invalidate this read

Operating margin is at 5.69%. Revenue grew 6.49% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.

Performance

Return analysis

Company profile

Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services.

CEOFrederick Lowery

SectorHealthcare

IndustryMedical - Distribution

Employees25,000

IPO dateNov 3, 1995

https://www.henryschein.com

Market multiples

Forward P/E—

EV/EBITDA12.65

Enterprise value$12.73B

Stock splits

Feb 8, 2019↑ Forward

Every 40 shares became 51

+27%

Sep 15, 2017↑ Forward

Every 1 shares became 2

+100%

Mar 1, 2005↑ Forward

Every 1 shares became 2

+100%

Profitability & growth

Revenue growth6.73%

Gross margin (FY2025)29.14%▼0.6ppvs FY2024

Operating margin (FY2025)5.75%0.0ppvs FY2024

ROE12.21%▲0.2ppvs FY2025

Analyst consensus

RatingBuy

Target price$92.33▲8.57%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 3, 2026

Q4 FY26 · EPS est $1.34 · Revenue est $3.47B

View

NASDAQ · HSIC

Henry Schein, Inc.

Healthcare · Medical - Distribution

$85.04▼ 1.99% ($1.73)at close

As of 4:00 PM ET

52-week

$61.95$92.18

Market cap

$9.69B

P/E

What the market price implies · Reverse DCF

To support a price of $85.04, this model requires Stage 1 FCFF to grow by 3.37%/yr over the next 5 years, compounded annually.

Historical FCFF grew by 4.07%/yr over the past 10 years. The required annual growth rate is 0.70 percentage points lower.

Selected forecast · Base scenario

4.07%/yr · Stage 1 default · years 1–5

Annual overrides take precedence over the Stage 1 default.

Market-implied · Other assumptions held fixed

3.37%/yr · Stage 1 · years 1–5

Stage 1 growth is solved while Stage 2 growth, terminal growth, discount inputs, and annual overrides remain fixed. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Cash-flow DCF

Price used

$85.04

Estimated value / share

$89.05

Base scenario

This estimate is 4.71% above the price used.

USD · TTM ending 2026-06-27

FCFF base normalized by replacing latest capex with the company's trailing median capex-to-revenue ratio.

Historical FCFF CAGR and the default growth rates are taken from the raw historical series. The valuation base is normalized for the current-period DCF.

Stage 1 4.07% · Stage 2 3.5% · Discount rate 7.89%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future free cash flow, discounted to its value today.

Price timestamp: Sep 17, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-27
Data refreshed: Sep 17, 2026, 10:20 PM UTC · cache

Why this method?

FCFF is positive, but the year-to-year swings are too large for a direct CAGR. Normalize the cash-flow base first, then run DCF.

Is FCFF positive and has it been for 3+ consecutive years? 26 consecutive positive FCFF years are available.

Is FCFF stable (not swinging >30% year to year)? The largest recent FCFF swing is 114.1%.

Price vs Fundamentals

Why The Stock Is Moving

Fundamentals are supporting the moveModerate confidence

1Y Price: 26.23%Revenue (TTM): 6.49%FCF (TTM): 50.56%P/FCF: 59th pct

What changed

The stock rose 26.23% over the last year. Revenue grew 6.49% over the trailing twelve months. Operating margin moved from 6.06% to 5.69%. Free cash flow grew 50.56% over the trailing twelve months.

What the market seems to be pricing

The stock move broadly lines up with stronger business momentum, and the shares are still only around the 59th percentile of their historical P/FCF range.

What would invalidate this read

Performance

Return analysis

Company profile

Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services.

CEOFrederick Lowery

SectorHealthcare

IndustryMedical - Distribution

Employees25,000

IPO dateNov 3, 1995

https://www.henryschein.com

Market multiples

Forward P/E—

EV/EBITDA12.65

Enterprise value$12.73B

Stock splits

Feb 8, 2019↑ Forward

Every 40 shares became 51

+27%

Sep 15, 2017↑ Forward

Every 1 shares became 2

+100%

Mar 1, 2005↑ Forward

Every 1 shares became 2

+100%

Profitability & growth

Revenue growth6.73%

Gross margin (FY2025)29.14%▼0.6ppvs FY2024

Operating margin (FY2025)5.75%0.0ppvs FY2024

ROE12.21%▲0.2ppvs FY2025

Analyst consensus

RatingBuy

Target price$92.33▲8.57%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 3, 2026

Q4 FY26 · EPS est $1.34 · Revenue est $3.47B

View